Christoph Brackmann
CIK: 0002048634
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovoCure Ltd
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Mar 4, 2026NVCR
NovoCure Ltd
Sale(S)Direct6.4K shares at avg. $13.31$85K - Mar 3, 2026NVCR
NovoCure Ltd
Award(A)Direct55.1K shares- - Nov 4, 2025NVCR
NovoCure Ltd
Tax Payment(F)Direct7K shares at avg. $12.23$86K - Jul 29, 2025NVCR
NovoCure Ltd
Purchase(P)Direct5K shares at avg. $11.50$58K - Jul 29, 2025NVCR
NovoCure Ltd
Purchase(P)Direct10K shares at avg. $11.63$116K - Jul 29, 2025NVCR
NovoCure Ltd
Purchase(P)Direct5K shares at avg. $11.60$58K - Mar 4, 2025NVCR
NovoCure Ltd
Award(A)Direct55K shares at avg. $18.19$1000K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 4, 2026 | NVCR NovoCure Ltd | Sale(S) | 6,412 | $13.31 | $85,314 | Direct |
| Mar 3, 2026 | NVCR NovoCure Ltd | Award(A) | 55,137 | - | $0 | Direct |
| Nov 4, 2025 | NVCR NovoCure Ltd | Tax Payment(F) | 7,033 | $12.23 | $86,014 | Direct |
| Jul 29, 2025 | NVCR NovoCure Ltd | Purchase(P) | 5,000 | $11.50 | $57,500 | Direct |
| Jul 29, 2025 | NVCR NovoCure Ltd | Purchase(P) | 10,000 | $11.63 | $116,300 | Direct |
| Jul 29, 2025 | NVCR NovoCure Ltd | Purchase(P) | 5,000 | $11.60 | $58,000 | Direct |
| Mar 4, 2025 | NVCR NovoCure Ltd | Award(A) | 54,975 | $18.19 | $999,995 | Direct |
1-7 of 7 transactions
About Brackmann Christoph
Brackmann Christoph (SEC CIK 0002048634) files insider reports with the SEC as Chief Financial Officer of NovoCure Ltd (NVCR).
Signal8 holds 5 ownership filings by Brackmann Christoph (1 Form 3, 4 Form 4), filed between Jan 6, 2025 and Mar 5, 2026. Those filings report 7 transactions, from Mar 4, 2025 to Mar 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Brackmann Christoph's filings is in WAYNE, PA.
Recent filings by Brackmann Christoph
- Mar 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 3, 2026: Grant or award of NVCR shares (Form 4, code A).
- Nov 4, 2025: Tax withholding of NVCR shares (Form 4, code F).
- Jul 29, 2025: Open-market purchases of NVCR shares (3 lines, Form 4, code P).
- Mar 4, 2025: Grant or award of NVCR shares (Form 4, code A).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director